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Abstract
Objective: Cancer patients may experience neurologic adverse effects, such as
alterations in neurocognitive function, as a consequence of chemotherapy. The
mechanisms underlying such neurotoxic syndromes remain poorly understood.
We here describe the temporal and regional effects of systemically administered
platinum-based chemotherapy on glucose metabolism in the brain of cancer
patients. Methods: Using sequential FDG-PET/CT imaging prior to and after
administration of chemotherapy, we retrospectively characterized the effects of
intravenously administered chemotherapy on brain glucose metabolism in a
total of 24 brain regions in a homogenous cohort of 10 patients with newly
diagnosed non-small-cell lung cancer. Results: Signiﬁcant alterations of glucose
metabolism were found in response to chemotherapy in all gray matter struc-
tures, including cortical structures, deep nuclei, hippocampi, and cerebellum.
Metabolic changes were also notable in frontotemporal white matter (WM) net-
work systems, including the corpus callosum, subcortical, and periventricular
WM tracts. Interpretation: Our data demonstrate a decrease in glucose metab-
olism in both gray and white matter structures associated with chemotherapy.
Among the affected regions are those relevant to the maintenance of brain plas-
ticity and global neurologic function. This study potentially offers novel insights
into the spatial and temporal effects of systemic chemotherapy on brain metab-
olism in cancer patients.
Introduction
Treatment of cancer with chemotherapy can be associated
with a wide range of adverse effects as a consequence of
toxicity to multiple organ systems. Dose-limiting toxicity
of chemotherapy frequently affects tissues that harbor
rapidly dividing cell populations, such as the gastrointesti-
nal tract and the hematopoietic system. While the central
nervous system (CNS) traditionally has been considered
much less vulnerable to the effects of chemotherapy,
recent clinical and experimental studies have revealed that
varying degrees of CNS toxicity might be more prevalent
than previously anticipated.
CNS toxicity from chemotherapy may include acute,
subacute, and delayed effects, and in some patients may
result in generalized neurological decline with cognitive
impairment, infrequently coupled with radiographic ﬁndings
of brain atrophy and white matter (WM) abnormalities.
1
Cognitive impairment as a late complication of chemother-
apy and radiation has long been observed in pediatric can-
cer patients.
2–6 Increasing survival rates of adult cancer
patients and analysis of survivors in longitudinal studies
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dence that chemotherapy can be associated with long-term
alteration of cognitive function.
7–21
Noteworthy, there are currently no standardized diag-
nostic tests available to monitor patients for potential
neurotoxicity, or to identify those individuals at risk.
Although neuroimaging studies have invariably demon-
strated nonspeciﬁc abnormalities, several recent prospec-
tive imaging studies with magnetic resonance imaging
(MRI), functional MRI (fMRI), and positron emission
tomography (PET) have supported the notion that struc-
tural and functional brain changes occur in a signiﬁcant
number of patients.
22–25
Neuroimaging and cognitive effects of chemotherapy
have been most widely studied in breast cancer patients.
26
Structural MRI studies in breast cancer patients treated
with systemic chemotherapy have revealed decreased regio-
nal volumes of gray and WM structures, including pre-
frontal and parahippocampal regions.
27 Consistent with
these early studies, subsequent MRI studies identiﬁed
reductions in overall brain volume,
28 and more speciﬁcally
in frontal, temporal, and cerebellar cortices in breast can-
cer patients examined longitudinally prior to and after che-
motherapy.
29 MRI studies using diffusion tensor imaging
(DTI) identiﬁed disseminated WM damage secondary to
systemic chemotherapy in breast cancer patients.
22,25,30,31
Functional imaging studies with fMRI have suggested that
regionally altered brain function in breast cancer patients
treated with chemotherapy correlates with cognitive
impairment and diminished executive function.
32–34 Very
little is known of the impact of chemotherapy on glucose
metabolism in the brain. Using [O-15] H2O and [F-18]
ﬂuorodeoxyglucose (FDG) PET in a cohort of breast can-
cer survivors, treated with chemotherapy 5–10 years prior,
the authors identiﬁed chronic gray matter (GM) altera-
tions in fronto-cortical, cerebellar, and basal ganglia activ-
ity.
35 Resting glucose metabolism in inferior-frontal brain
regions correlated with impaired short-term memory func-
tion in the same patient cohort.
35 A subsequent FDG-PET/
CT brain imaging study found a correlation between circu-
lating pro-inﬂammatory cytokines, cognitive complaints,
and regionally impaired glucose metabolism in the medial
prefrontal cortex and anterior temporal cortex in a
cohort of breast cancer survivors monitored over 1 year
36;
however, imaging data prior to administration of chemo-
therapy were not obtained in both studies.
Insights into potential mechanisms of neurotoxicity fol-
lowing chemotherapy have come from preclinical stud-
ies.
37 We have previously shown both in vitro and in vivo
that diverse classes of conventional chemotherapeutic
agents, such as antimetabolites and alkylating agents may
be harmful to neural progenitor cell populations relevant
for the maintenance of normal brain function, WM integ-
rity, gliogenesis, and neurogenesis.
38–42 In particular, plat-
inum compounds and other alkylating agents can be
harmful to the CNS with potentially long-lasting effects
on neural repair and brain plasticity.
38
Using FDG-PET in combination with an advanced
imaging analysis technology speciﬁcally developed for this
study, we here describe the temporal and regional effects
of platinum-based chemotherapy on resting glucose
metabolism in the brain of a homogenous cohort of
non-small-cell lung cancer (NSCLC) patients followed
longitudinally pre- and post treatment. We retrospectively
analyzed brain regions of interest (ROI) in GM, WM,
and germinal zones, thought to be relevant for the main-
tenance of brain plasticity in the adult CNS.
Patients and Methods
Patient selection criteria
We searched the Brigham & Women’s Hospital (BWH)
Nuclear Medicine clinical database between 2005 and
2012 for patients who underwent serial FDG-PET scans
as part of cancer staging at both baseline and follow-up
after receiving chemotherapy.
Based on our preclinical studies demonstrating preferen-
tial neurotoxic effects on brain plasticity with platinum
compounds and other alkylating agents, and in order to
identify a homogenous patient population suitable for the
objective of this imaging study, we focused our search on
patients aged 18, or older, with newly diagnosed non-
small-cell lung cancer receiving a platinum-based treatment
protocol as part of their initial management. Importantly,
any patient with active or previous neurologic disease or
with a history of prior chemotherapy (for any cancer or
condition) was excluded. Patients with evidence of brain
metastasis were also excluded from this study. Patients were
required to have a normal renal and liver function both
pre- and post chemotherapy. In addition, patients taking
any medications that potentially could inﬂuence brain
function and brain metabolism (e.g., benzodiazepines,
opiates, narcotics, antidepressants, and steroids) were not
eligible for this study.
We identiﬁed a total of 541 patients who underwent
PET imaging as part of their staging studies for non-
small-cell lung cancer between 2005 and 2012; however,
only 156 patients underwent multiple longitudinal PET
studies. Of these, 146 patients were excluded from the
study, since they did not meet the strict eligibility criteria
noted above (e.g., no prior chemotherapy, history of
neurological or psychiatric disease, metastatic disease to
the brain, longitudinal PET images not obtained at the
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potential effect on brain function, etc.).
This retrospective study was reviewed and approved by
the institutional review board (IRB). All patients had
clinically scheduled whole-body staging FDG-PET/CT
studies prior to initiation of cancer therapy. The BWH
clinical whole-body PET/CT protocol includes whole-brain
imaging, creating a unique database for longitudinal stud-
ies, with a baseline scan prior to treatment and at least
one follow-up scan after starting chemotherapy. The
design of this study therefore provided the unique oppor-
tunity to use each patient’s baseline imaging as a control
for subsequent scans.
Clinical imaging protocol
Patients were injected intravenously with
18F-FDG at a
standard dose of 20 mCi for whole-body imaging in two-
dimensional mode. PET/CT images were acquired on a
Discovery ST PET/CT scanner (General Electric, Milwau-
kee, WI) at 45–60 min after tracer injection. The
unenhanced CT scan was performed ﬁrst using the
following parameters: 140 kVp, 15 mA, 30 cm DFOV,
pitch 0.531:1, 32 slice helical, 3.75 mm slice thickness,
and 10.62 mm/rotation. The CT data were reconstructed
using a ﬁltered back projection algorithm and a
128 9 128 matrix, ramp cutoff of 5.8 mm, with 30 cm
trans-axial ﬁeld of view. The PET data were reconstructed
using an iterative ordered subsets expectation maximiza-
tion (OSEM) algorithm (28 subsets, two iterations), a
standard z axis ﬁlter, 3.74 mm post ﬁlter, a 128 9 128
matrix, and a DFOV 43.6 mm. Random coincidences
were estimated using single crystal event rates.
Plasma glucose concentration was measured prior to
each scan by ﬁnger stick. All patients were instructed to
take nothing by mouth but water for at least 4–6 h prior
to the study. Blood glucose levels were not statistically
different (P = 0.34; paired t-test) between baseline (mean
of 106.2  4.6 mg/dL [SEM]; 95% CI: 95.7–116.8 mg/
dL) and at time of follow-up PET scans post chemother-
apy (mean of 114.0  9.5 mg/dL [SEM]; 95% CI: 92.1–
135.9 mg/dL). This variation is similar to the variation
expected with time in normal individuals. The lumped con-
stant (LC), deﬁned as the conversion factor between the net
uptake of FDG and glucose,
43 was assumed to be constant
over time, given the lack of evidence that LC values change
in the setting of chemotherapy. All subjects rested quietly
during the 45- to 60-min FDG uptake period with eyes
open in a dark room per standard clinical protocol.
Image processing
We used 3DSlicer (www.slicer.org)
44 and BRAINSﬁt
(http://hdl.handle.net/1926/1291), an innovative open-
source imaging analysis technology, for image processing.
The technology was modiﬁed for use in brain PET imag-
ing. First, whole-body PET/CT images were converted
from DICOM format to Nearly Raw Raster Data (NRRD)
format, 3DSlicer’s native format for imaging manipula-
tion and processing. The whole-body PET and CT images
were cropped to isolate the brain image data sets. Two
sets of PET and CT brain images were coregistered to
each other: one set performed at baseline prior to initiat-
ing chemotherapy and the other after chemotherapy. This
coregistration process resulted in matching PET and CT
axial images, in which corresponding voxels or ROI
drawn in any of the image matrixes could be accurately
mapped to the same anatomic location within each data
set. Whenever available, MR images were also processed
and coregistered to PET and CT to assist with the identi-
ﬁcation of anatomic structures.
ROI
Using coregistered images, a total of 24 brain ROI,
including 13 GM, seven WM, and four germinal zone
regions (subventricular zone and medial temporal lobe/
hippocampus), were contoured on each subject’s scan, as
summarized in Table 1. ROI were placed manually (using
3DSlicer) by a blinded co-Investigator (L. H.). The size of
each ROI varied according to the size of the structure
(smaller for small structures such as hippocampus and
Table 1. Regions of interest (ROI) analyzed prior to and after chemotherapy.
Gray matter structures (n = 13) White matter structures (n = 7) Germinal zones (n = 4)
Caudate head (right/left) Paraventricular white matter (right/left) Medial temporal lobe/hippocampus (right/left)
Thalamus (right/left) Corpus callosum (genu) Subventricular zone (right/left)
Frontal cortex (right/left) Corpus callosum (splenium)
Parietal cortex (right/left) Subcortical white matter (right/left)
Cerebellar cortex (right/left) Cerebellar white matter (right)
Posterior cingulate gyrus
Olfactory gyrus (right/left)
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frontal GM). In each case, each ROI was placed on the
axial slice that best demonstrated the region. Since PET
scans were coregistered to one another, this allowed for
duplication of ROI to corresponding areas of the brain
on each modality at each time point. This method opti-
mizes reproducibility in ROI placement. An example of
the ROI placement identiﬁed on PET and corresponding
MR images is shown in Figure 1. From the ROI,
SUVmean (standardized uptake valuemean) and SUVmax
were obtained. SUVmean quantiﬁes the average SUV in the
region of interest. SUVmax deﬁnes the voxel of highest
metabolism within the entire region. SUVs were analyzed
longitudinally over time for each patient in all ROI, to
include a pre- and post-chemotherapy data set.
Statistical analysis
Results were expressed as the mean and its corresponding
standard error (SE), and 95% conﬁdence intervals (CI).
Right versus left comparisons of metabolic activity in
cerebral regions as a function of treatment were per-
formed within each patient using the paired t-test (two-
tailed). P<0.05 was used to deﬁne statistical signiﬁcance.
In addition, we used multivariate analysis of variance
(MANOVA) to determine possible differences among
brain regions within GM, WM, and germinal zones.
P < 0.05 was used to deﬁne statistical signiﬁcance.
Results
Patient characteristics and study design
A homogenous group of 10 adult subjects with newly
diagnosed NSCLC were evaluated in this study (mean age
63, range 48–78, including seven males and three
females). All patients received initial treatment with con-
ventional chemotherapy consisting of a platinum-based
regimen, as summarized in Table 2. In addition, two sub-
jects subsequently also received Pemetrexed (Alimta), a
folate antagonist, and three subjects received additional
chemotherapy with bevacizumab (Avastin), a humanized
monoclonal antibody directed against vascular endothelial
growth factor (VEGF). Baseline brain imaging with FDG-
PET/CT was performed prior to initiating chemotherapy.
Restaging studies were performed after a mean of four
cycles of chemotherapy (range 1–7 cycles), corresponding
to a mean time interval of 181 days or 6 months (range
88–402 days) between baseline and follow-up scans.
Patients were off active chemotherapy at the time of
follow-up PET/CT for a mean of 11 days (range 2–
28 days).
Figure 1. Regions of interest (ROI) placement on PET and corresponding magnetic resonance images. The ﬁgure shows an example of the ROI
placement in gray and white matter regions and in germinal zones on magnetic resonance imaging (upper panel) and coregistration with
corresponding PET scans (lower panel). From a total of 24 regions both SUVmean and SUVmax were obtained. SUVs were analyzed longitudinally
over time for each patient in all ROI, to include a pre- and postchemotherapy data set. (1,2): right and left cerebellar cortex; (3,4): right and left
medial temporal lobe and hippocampus; (5,6): right and left orbitofrontal cortex/olfactory gyrus; (7,8): right and left anterior and posterior
subventricular zone; (9,10): right and left caudate nucleus; (11,12): right and left thalamus; (13,14): right and left periventricular white matter;
(15): corpus callosum (splenium); (16,17): right and left frontal cortex; (18,19): right and left subcortical white matter; Not shown in this
representative image are: right and left parietal cortex, corpus callosum (genu), posterior cingulate, and cerebellar white matter. PET, positron
emission tomography; SUV, standardized uptake value.
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metabolism in GM structures following
systemic platinum-based chemotherapy
Signiﬁcant decreases in resting brain glucose metabolism
between baseline and follow-up imaging were identiﬁed
in all 13 GM structures in response to platinum-based
chemotherapy (Tables 3 and 4). Using SUVmax criteria,
reductions of up to 20% (SE = 3.0%; 95% CI, 14–26%)
were observed in resting brain glucose metabolism in all
GM structures, including bilateral frontal and parietal
cortices, cerebellum, deep nuclei, and posterior cingulate
gyrus (Table 3). Most profoundly affected were the right
frontal cortex (decrease by 24.0% [SE = 6.0%], [95% CI,
11–38%]; P = 0.004), left frontal cortex (decrease by
23.0% [SE = 5.4%], [95% CI, 11–35%]; P = 0.004), and
the bilateral olfactory gyri (decrease by 22.0%
[SE = 5.0%], [95% CI, 12–33%]; P = 0.002). Compari-
sons of SUVmean pre- and post chemotherapy also dem-
onstrated similar decreases in resting brain glucose
metabolism, most notably in the right frontal cortex
(decrease by 26.0% [SE = 6.0%], [95% CI, 13–40%];
P = 0.004), left frontal cortex (decrease by 23.0%
[SE = 6%], [95% CI, 10–35%]; P = 0.004), and bilateral
olfactory gyri (decrease by 23.0% [SE = 4%], [95% CI,
14–33%]; P = 0.001) (Table 4). The mean overall reduc-
tion in SUVmean values in all 13 GM ROI was 22.0%
(SE = 1.5%), (95% CI, 19–25%).
Differential impact on WM structures
following platinum chemotherapy
Although an overall decrease of 10% in SUVmax and
SUVmean was seen in all WM structures (Tables 3 and 4),
Table 3. Max SUV of regions of interest.
Region of
Interest
Max SUV
(SE) baseline
95%
CI baseline
Max SUV
(SE) follow-up
95%
CI follow-up
P-value
baseline vs.
follow-up
Avg. %
change
baseline vs.
follow-up 95% CI
Gray matter
Right caudate head 9.85 (1.08) 7.4–12.3 8.23 (1.10) 5.8–10.7 0.017 17.0 0.32 to 0.03
Left caudate head 9.54 (0.83) 7.7–11.4 8.05 (1.10) 5.6–10.5 0.021 17.0 0.30 to 0.05
Right thalamus 10.26 (0.99) 8.4–12.1 8.10 (0.99) 5.9–10.3 0.014 21.0 0.36 to 0.06
Left thalamus 10.34 (0.83) 8.5–12.2 8.24 (0.95) 6.1–10.4 0.012 20.0 0.34 to 0.06
Right frontal cortex 12.05 (0.96) 9.9–14.2 9.07 (1.01) 6.8–11.4 0.004 24.0 0.38 to 0.11
Left frontal cortex 11.35 (0.97) 9.1–13.5 8.72 (0.96) 6.5–10.9 0.004 23.0 0.35 to 0.11
Right parietal cortex 11.24 (0.92) 9.2–13.3 8.92 (0.99) 6.7–11.2 0.014 20.0 0.36 to 0.04
Left parietal cortex 10.82 (1.03) 8.5–13.1 8.55 (1.00) 6.3–10.8 0.015 20.0 0.35 to 0.05
Right cerebellum 9.80 (0.84) 7.9–11.7 8.02 (0.80) 6.2–9.8 0.020 17.0 0.31 to 0.03
Left cerebellum 9.75 (0.85) 7.8–11.7 7.86 (0.76) 6.1–9.6 0.021 18.0 0.32 to 0.04
Post cingulate gyrus 11.50 (1.06) 9.1–13.9 9.11 (1.04) 6.7–11.5 0.006 20.0 0.34 to 0.07
Right olfactory gyrus 9.92 (0.67) 8.4–11.4 7.75 (0.70) 6.2–9.3 0.001 22.0 0.33 to 0.11
Left olfactory gyrus 9.93 (0.67) 8.4–11.4 7.77 (0.76) 6.1–9.5 0.002 22.0 0.34 to 0.07
White matter
Right paraventricular WM 5.53 (0.90) 4.9–6.2 4.80 (1.00) 4.1–5.5 0.007 13.0 0.22 to 0.05
Left paraventricular WM 5.42 (1.05) 4.6–6.2 4.69 (1.02) 4.0–5.4 0.120 (n.s.) 11.0 0.29 to 0.08
Corpus callosum 4.97 (1.15) 4.2–5.8 4.15 (1.20) 3.3–5.8 0.004 17.0 0.26 to 0.07
Right subcortical WM 4.93 (2.92) 2.8–7.0 4.53 (1.43) 3.5–5.5 0.550 (n.s.) 0.0 0.19 to +0.18
Left subcortical WM 5.08 (3.33) 2.7–7.5 4.16 (1.45) 3.1–5.2 0.212 (n.s.) 10.0 0.26 to +0.05
Posterior corpus callosum 7.56 (5.80) 3.4–11.7 6.04 (4.17) 3.1–9.0 0.059 (n.s.) 13.0 0.30 to +0.11
Cerebellar WM 8.87 (5.31) 5.1–12.7 7.36 (3.68) 4.7–10.0 0.129 (n.s.) 9.0 0.29 to 0.08
Germinal zone
Right hippocampus 6.90 (1.55) 5.8–8.0 6.31 (2.08) 4.8–7.8 0.150 (n.s.) 9.0 0.21 to +0.03
Left hippocampus 7.00 (1.91) 5.6–8.4 6.24 (1.93) 4.9–7.6 0.106 (n.s.) 9.0 0.23 to +0.04
Right SVZ 5.35 (1.45) 4.3–6.4 4.62 (1.32) 3.7–5.6 0.009 13.0 0.23 to 0.03
Left SVZ 4.60 (1.21) 3.7–5.5 4.23 (1.43) 3.2–5.3 0.121 (n.s.) 9.0 0.20 to +0.02
All gray matter ROI 10.49 (0.23) 10.00–10.98 8.34 (0.25) 7.84–8.84 0.0001 20.0 0.14 to 0.26
All white matter ROI 6.05 (0.43) 5.19–6.91 5.10 (0.30) 4.51–5.70 0.0001 10.0 0.05 to 0.16
Germinal zones 5.96 (0.29) 5.38–6.54 5.33 (0.30) 4.73–5.93 0.0002 10.0 0.05 to 0.15
SUV, standardized uptake value; WM, white matter; SVZ, subventricular zone; ROI, regions of interest; SE, standard error; CI, conﬁdence interval;
n.s., not signiﬁcant.
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seven structures: the right paraventricular WM (decrease
by 13% [SE = 4%], [95% CI, 5–22%]; P = 0.007) and
the genu of the corpus callosum (decrease by 17%
[SE = 4%], [95% CI, 7–26%]; P = 0.004) (Table 3).
Consistent with these ﬁndings, signiﬁcant reductions in
SUVmean were also seen in the right paraventricular WM
(decrease by 12% [SE = 5%], [95% CI, 0.8–22%];
P = 0.018) and the genu of the corpus callosum (decrease
by 14% [SE = 5%], [95% CI, 3–26%]; P = 0.018)
(Table 4).
Platinum-based chemotherapy decreases
glucose metabolism in germinal zones of
the CNS
To assess the impact of chemotherapy on germinal
zones of the adult CNS, deﬁned as regions of the brain
that harbor neural progenitor cell and stem cell popula-
tions with the ability to respond to injury and to dif-
ferentiate into neuronal and glial lineages, we analyzed
changes in glucose metabolism in bilateral subventricu-
lar zones (SVZ) and bilateral hippocampi in the medial
temporal lobes. Signiﬁcant reductions in SUVmax were
noted in the right subventricular zone (decrease by
13% [SE = 4%], [95% CI, 3–23%]; P = 0.009) and in
the mean glucose metabolism both in the right subven-
tricular zone (decrease by 12% [SE = 5%], [95% CI,
0.2–24%]; P = 0.036) and in the left subventricular
zone (decrease by 11.0% [SE = 5%], [95% CI, 0.4–
23%]; P = 0.043). While reduction of hippocampal glu-
cose metabolism was also noted in terms of both
SUVmean and SUVmax, these changes did not reach sig-
niﬁcance. However, overall reductions across all germi-
nal zone structures reached 11% in SUVmean and 10%
in SUVmax.
Table 4. Mean SUV of regions of interest.
Region of
interest
Mean SUV
(SE) baseline
95% CI
baseline
Mean SUV
(SE)
follow-up
95% CI
follow-up
P-value
baseline vs.
follow-up
Avg. %
change
baseline vs.
follow-up 95% CI
Gray matter
Right caudate head 8.35 (0.74) 6.7–10.0 6.78 (2.60) 4.9–8.6 0.008 20.0 0.33 to 0.07
Left caudate head 8.38 (0.70) 6.8–10.0 6.77 (2.57) 4.9–8.6 0.004 20.0 0.32 to 0.08
Right thalamus 9.02 (0.81) 7.4–10.6 7.00 (2.57) 5.2–8.8 0.010 22.0 0.36 to 0.08
Left thalamus 9.07 (0.71) 7.5–10.7 7.19 (2.50) 5.4–9.0 0.012 20.0 0.33 to 0.07
Right frontal cortex 10.33 (0.78) 8.6–12.1 7.55 (2.52) 5.7–9.4 0.004 26.0 0.40 to 0.10
Left frontal cortex 9.94 (0.80) 7.8–11.4 7.41 (2.50) 5.6–9.2 0.004 23.0 0.36 to 0.07
Right parietal cortex 9.61 (0.80) 7.8–11.4 7.60 (2.57) 5.8–9.4 0.014 20.0 0.35 to 0.05
Left parietal cortex 9.27 (0.87) 7.3–11.2 7.22 (2.46) 5.4–9.0 0.008 21.0 0.34 to 0.08
Right cerebellum 8.35 (0.61) 7.0–9.7 6.81 (2.03) 5.4–8.3 0.016 18.0 0.32 to 0.04
Left cerebellum 8.40 (0.67) 6.9–9.9 6.80 (1.92) 5.4–78.2 0.010 18.0 0.30 to 0.06
Post cingulate gyrus 10.19 (0.89) 8.2–12.2 8.14 (2.65) 6.2–10.0 0.008 19.0 0.33 to 0.06
Right olfactory gyrus 8.94 (0.62) 7.5–10.3 6.82 (1.86) 5.5–8.2 0.001 23.0 0.33 to 0.14
Left olfactory gyrus 9.02 (0.63) 7.6–10.4 6.88 (1.96) 5.5–8.3 0.001 23.0 0.33 to 0.14
White matter
Right paraventricular WM 4.17 (0.22) 3.7–4.7 3.63 (0.50) 3.3–4.0 0.018 12.0 0.22 to 0.008
Left paraventricular WM 3.69 (0.24) 3.2–4.2 3.26 (0.60) 2.8–3.7 0.063 (n.s.) 10.0 –0.23 to +0.04
Corpus callosum (genu) 3.83 (0.18) 3.4–4.2 3.29 (0.82) 2.7–4.2 0.018 14.0 –0.26 to 0.04
Right subcortical WM 3.71 (0.40) 2.8–4.6 3.38 (.078) 2.8–3.9 0.294 (n.s.) 6.0 –0.20 to +0.09
Left subcortical WM 3.69 (0.42) 2.7–4.6 3.31 (0.75) 2.8–3.8 0.215 (n.s.) 7.0 –0.20 to +0.06
Corpus callosum (splenium) 4.62 (0.18) 3.0–6.3 4.01 (1.74) 2.8–5.3 0.098 (n.s.) 9.0 –0.21 to +0.04
Cerebellar WM 6.00 (0.51) 4.9–7.1 5.32 (1.42) 4.3–6.3 0.178 (n.s.) 9.0 –0.27 to +0.09
Germinal Zone
Right hippocampus 6.40 (0.49) 5.3–7.5 5.71 (1.87) 4.4–7.0 0.081 (n.s.) 11.0 –0.23 to +0.01
Left hippocampus 6.43 (0.56) 5.2–7.7 5.77 (1.79) 4.5–7.1 0.065 (n.s.) 9.0 –0.21 to +0.02
Right SVZ 4.53 (0.38) 3.7–5.4 3.94 1.01) 3.2–4.7 0.036 12.0 –0.24 to +0.002
Left SVZ 4.04 (0.34) 3.3–4.8 3.57 (1.08) 2.8–4.3 0.043 11.0 –0.23 to +0.004
All gray matter ROI 9.12 (0.20) 8.72–9.52 7.04 (0.19) 6.7–7.41 0.00003 22.0 0.25 to 0.19
All white matter ROI 4.24 (0.18) 3.89–4.60 3.74 (0.14) 3.5–4.0 0.00001 9.0 0.14 to 0.05
Germinal zones 5.35 (0.28) 4.79–5.91 4.75 (0.28) 4.19–5.31 0.00007 11.0 0.16 to 0.06
SUV, standardized uptake value; WM, white matter; SVZ, subventricular zone; ROI, regions of interest; SE, standard error; CI, conﬁdence interval;
n.s., not signiﬁcant.
794 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Chemotherapy Alters Brain Glucose Metabolism L. L. Horky et al.Collectively, signiﬁcant decreases in resting glucose
metabolism were seen globally throughout the brain,
including gray and WM structures, and regions consid-
ered relevant for maintenance of brain plasticity. Figure 2
shows an example (subject #10) of whole-body and brain
PET imaging, revealing a profound decrease in global and
regional brain metabolism by 44% following chemother-
apy. In order to identify the potential differences in glu-
cose metabolism among brain regions within GM, WM,
and germinal zones, we applied MANOVA. GM regions
were signiﬁcantly more affected than WM regions
(P = 0.005) and germinal zones (P = 0.002), suggesting
regional differences in the effects of chemotherapy on the
brain. However, even though SUV was signiﬁcantly
diminished in both gray and WM regions and germinal
zones, no statistical difference was detected between
speciﬁc subregions of GM, WM, or germinal zones.
Discussion
An increasing body of literature suggests that chemother-
apy can be associated with delayed and persistent neuro-
logic adverse effects, even in patients treated for non-CNS
tumors. Commonly reported symptoms include cognitive
impairment characterized by decreased attention, concen-
tration, memory and executive function, and infrequently
WM damage identiﬁed on brain imaging.
40 Despite these
clinically well-recognized symptoms and ﬁndings, surpris-
ingly little is known about the functional mechanisms
underlying such adverse effects.
Using FDG-PET in combination with an advanced
imaging analysis technology, we here describe the tempo-
ral and spatial pattern of platinum-based chemotherapy
on resting glucose metabolism in the brain of a homoge-
nous cohort of non-small-cell lung cancer patients treated
with a comparable chemotherapy regimen. While all
patients were treated with a platinum-based regimen, a
contribution of other chemotherapeutic agents (e.g.,
Taxol, Etoposide, Alimta, Avastin, or Gemcitabine) to the
ﬁndings in this study cannot be ruled out. The design of
the study provided the unique opportunity to use each
patient’s imaging data set prior to administration of che-
motherapy as an internal control for follow-up imaging
during the course and after completion of chemotherapy.
Signiﬁcant decreases in glucose metabolism were noted
across all GM structures, including bilateral frontal, parie-
tal and cerebellar cortices, and bilateral basal ganglia with
a mean overall reduction of 22%. Decrease in resting
glucose metabolism affected GM structures in both hemi-
spheres in a comparable and overall symmetric distribu-
tion. Chemotherapy was also associated with a decrease
in glucose metabolism in paraventricular and subcortical
WM tracts, corpus callosum, and cerebellar WM. It
Figure 2. Alterations of resting state glucose metabolism prior to and
after chemotherapy. Top panel: axial brain images in a representative
patient (subject #10, see Table 3), demonstrating normal resting brain
metabolism on the “pre-chemo” image and a reduction by 44% in the
“post-chemo” image (SUVmax decreases from 10.0 to 5.6). In this
“rainbow” color display, the areas with highest glucose metabolism
are shown as orange to red. Areas with lowest glucose metabolism are
shown as green to blue. Lower panel: maximum intensity projection
PET images of the head through the thighs in the same patient
showing the change in resting whole-body metabolism between
baseline (prechemotherapy) and follow-up (post chemotherapy)
imaging. In “hot lava” color display, high metabolism is indicated
by yellow to white colors and low metabolism is indicated by red
and black. The tumor in the right lung demonstrates a higher
metabolism at baseline and lower metabolism on follow-up,
compatible with a reduction in tumor size and favorable response to
treatment (SUVmax decreases from 12.2 to 9.8, a decrease by 20%).
In the liver, serving as a control organ, the values for SUVmax do not
change between baseline and follow-up, demonstrating consistency in
technique. As an additional ﬁnding on both image sets, physiologic
radiotracer excretion is seen in kidneys and bladder. PET, positron
emission tomography; SUV, standardized uptake value.
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transient or might be indicative of subsequent WM
changes observed by others as a consequence of chemo-
therapy.
22,25,30 We found that altered glucose metabolism
in WM tracts was most notable in the right frontotempo-
ral WM and corpus callosum, but overall was not signiﬁ-
cantly different between hemispheres.
To assess the impact of platinum-based chemotherapy
on the germinal zones of the adult CNS, known to be
highly vulnerable to chemotherapy based on preclinical
studies,
38 we included bilateral hippocampi and SVZ in our
analysis. Strikingly, exposure to chemotherapy resulted in a
signiﬁcant overall decrease of resting glucose metabolism by
12–13% in the bilateral SVZ. A decrease of 10–11% in glu-
cose metabolism was also notable in bilateral hippocampi,
although this change did not reach level of signiﬁcance.
While the biological consequences of this ﬁnding remain
unknown, we speculate that signiﬁcant impairment of glu-
cose metabolism in the lateral SVZ might lend support to
the current concept of the cell biological mechanisms
underlying chemotherapy-associated CNS toxicity.
Collectively, GM structures appeared signiﬁcantly more
affected than WM and germinal zones. We were unable to
identify signiﬁcant differences, however, within subregions
of GM, WM, or germinal zones.
To our knowledge, this represents the ﬁrst functional
imaging study in which quantitative changes in FDG-PET
have been studied in both gray and WM structures longi-
tudinally in response to chemotherapy. Our ﬁndings of
differential impact of chemotherapy on brain glucose
metabolism in distinct brain regions potentially offers
novel insights into adverse neurologic consequences
observed in cancer patients treated with chemotherapy.
We would like to point out that a potential confounding
factor in our ﬁndings could be a possible change in the
lumped constant (LC), deﬁned as the conversion factor
between the net uptake of FDG and glucose
43 as a conse-
quence of chemotherapy. However, we are not aware of any
data in the literature in this regard and assumed the LC to be
constant over time and unaffected by systemic chemotherapy.
Our study extends the current body of literature by
evaluating the effects of platinum-based chemotherapy in
a cohort of non-small-cell lung cancer patients, whereas
most other studies have focused on chemotherapy-treated
breast cancer patients.
26
We hypothesize that the integrity of germinal zones
and maintenance of neural progenitor cell populations
are relevant for regenerative processes following toxic
insults to the CNS, and that exhaustion of progenitor cell
pools in germinal zones might play an important role in
long-term neurological function of cancer patients.
42
The ﬁndings of this PET imaging study might represent
a functional correlate of cell biological changes seen in
preclinical studies,
38,39 by revealing metabolic changes in
gray and WM regions, as well as in germinal zones fol-
lowing platinum-based chemotherapy.
To the best of our knowledge, only two other studies
have used PET imaging to evaluate the impact of chemo-
therapy on the brain – both in breast cancer survivors
and without baseline imaging prior to chemotherapy.
The ﬁrst study by Silverman et al. used [O-15] H2O
and FDG-PET in breast cancer survivors treated with che-
motherapy more than 5 years prior, and identiﬁed
chronic GM alterations of resting glucose metabolism in
fronto-cortical, cerebellar, and basal ganglia activity.
35
Impaired glucose metabolism in inferior-frontal brain
regions correlated with impaired short-term memory
function.
35 Using FDG-PET in breast cancer patients pre-
viously treated with chemotherapy, the same group later
reported a potential correlation between circulating pro-
inﬂammatory cytokines, cognitive complaints, and region-
ally impaired glucose metabolism in the medial prefrontal
cortex and anterior temporal cortex.
36 Both studies were
limited by the lack of imaging data prior to administra-
tion of chemotherapy, instead using non-chemotherapy-
treated cancer patients as controls.
Recent functional imaging studies with fMRI have
suggested that regionally altered brain function and
disruption of resting state functional connectivity patterns
correlate with cognitive impairment and decreased
executive function in breast cancer patients treated with
chemotherapy.
32–34,45
While neurocognitive function was not formally
assessed in our study, 60% of patients reported either sig-
niﬁcant memory impairment and/or mood alterations
during the course of treatment, perhaps suggestive of
functional neurological consequences of cancer therapy.
We intend to correlate FDG-PET data with formal neuro-
psychological testing in future prospective studies.
It remains unclear at this point whether the observed
chemotherapy effects on the brain represent acute, sub-
acute, or delayed changes, since all follow-up FDG-PET
scans were performed after a mean of four cycles of che-
motherapy, corresponding to a mean time interval of
6 months between baseline and follow-up scans. At the
time of follow-up PET/CT, patients were off active che-
motherapy for a mean of 11 days (range 2–28 days).
Therefore, the effects of chemotherapy could be the result
of acute, subacute, or delayed effects. In addition, cumu-
lative effects cannot be ruled out.
The long-term neurologic consequences of functional
changes of resting glucose metabolism remain unknown.
It may be noteworthy, however, that one of the subjects
in our study (ID #10; Table 2) developed a marked
reduction of overall brain volume after four cycles of ther-
apy with carboplatin/taxol and subsequent bevacizumab,
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20%, measured on MRI using 3DSlicer, over the course
of <5 months.
It has been a daunting challenge to monitor and pre-
dict neurotoxicity in individual patients receiving chemo-
therapy. Despite multiple limitations, cognitive testing has
been the most accessible and cost-effective approach. This
study is hypothesis generating in this regard and suggests
that serial FDG-PET studies of the brain might represent
a potential biomarker of neurotoxicity during cancer
treatment. Future prospective studies with combined PET
and structural neuroimaging and longitudinal cognitive
assessment might therefore offer novel mechanistic and
biological insights into the vulnerability of the CNS to
chemotherapy.
Collectively, this study provides novel insights into (1)
changes in regional resting glucose metabolism in response
to platinum-based chemotherapy in a cohort of lung cancer
patients, and (2) alterations of resting metabolic activity in
germinal zones (hippocampus, subventricular zone, olfac-
tory bulb), which are areas considered relevant to endoge-
nous CNS repair and maintenance of overall brain
function. Future prospective studies combining advanced
neuroimaging modalities (e.g., PET/MRI) with longitudinal
assessment of neurocognitive function will allow further
characterization of the long-term structural and functional
consequences of chemotherapy in cancer patients, and to
identify and validate the potential imaging biomarkers of
neurotoxicity associated with chemotherapy.
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